Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 6/6 |
Financial Health | 5/6 |
Dividends | 5/6 |
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥19.44 |
52 Week High | CN¥33.29 |
52 Week Low | CN¥17.80 |
Beta | 0.23 |
1 Month Change | -9.58% |
3 Month Change | -13.37% |
1 Year Change | -35.18% |
3 Year Change | 3.05% |
5 Year Change | 118.08% |
Change since IPO | 58.37% |
Recent News & Updates
Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?
Mar 01Shareholder Returns
2603 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -1.9% | -0.7% | -0.2% |
1Y | -35.2% | -15.9% | -17.8% |
Return vs Industry: 002603 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 002603 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
2603 volatility | |
---|---|
2603 Average Weekly Movement | 4.4% |
Pharmaceuticals Industry Average Movement | 7.9% |
Market Average Movement | 8.9% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 002603 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002603's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 15,074 | Xiang Jun Wu | www.yiling.cn |
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for respiratory health, cardiovascular disease, diabetes mellitus, oncology, urologic disease, sleep-improving, and anti-aging. The company also provides dietary supplements, health food and drinks, disinfection products, and personal protective equipment, as well as formula granules.
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Fundamentals Summary
2603 fundamental statistics | |
---|---|
Market cap | CN¥32.91b |
Earnings (TTM) | CN¥2.71b |
Revenue (TTM) | CN¥13.16b |
12.0x
P/E Ratio2.5x
P/S RatioIs 2603 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2603 income statement (TTM) | |
---|---|
Revenue | CN¥13.16b |
Cost of Revenue | CN¥4.88b |
Gross Profit | CN¥8.28b |
Other Expenses | CN¥5.57b |
Earnings | CN¥2.71b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 27, 2024
Earnings per share (EPS) | 1.62 |
Gross Margin | 62.90% |
Net Profit Margin | 20.56% |
Debt/Equity Ratio | 13.5% |
How did 2603 perform over the long term?
See historical performance and comparison